Design of cluster-randomized trials of quality improvement interventions aimed at medical care providers

被引:56
作者
Glynn, Robert J.
Brookhart, M. Alan
Stedman, Margaret
Avorn, Jerry
Solomon, Daniel H.
机构
[1] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Dept Med, Boston, MA 02120 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
关键词
cluster randomized trials; design effect; contamination; quality improvement; intraclass correlation;
D O I
10.1097/MLR.0b013e318070c0a0
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Randomized trials aimed at improving the quality of medical care often randomize the provider. Such trials are frequently embedded in health care systems with available automated records, which can be used to enhance the design of the trial. Methods: We consider how available information from automated records can address each of the following concerns in the design of a trial: whether to randomize individual providers or practices; clustering of outcomes among patients in the same practice and its impact on study size; expected heterogeneity in adherence and the response to the intervention; eligibility criteria and the trade-offs between generalizability and internal validity; and blocking or matching to alleviate covariate imbalance across practices. Results: Investigators can use available information from an automated database to estimate the amount of clustering of patients within providers and practices, and these estimates can inform the decision on whether to randomize at the level of the patient, the provider, or the practice. We illustrate calculation of the anticipated design effect for a proposed cluster-randomized trial and its implications for sample size. With available claims data, investigators can apply focused eligibility criteria to exclude subjects and providers with expected low compliance or lower likelihood of benefit, although possibly at some loss of generalizability. Chance imbalances in covariates are more likely when randomization occurs at the level of the practice than at the level of the patient, so we propose a matching score to limit such imbalances by design. Conclusions: Challenges to compliance, expected small effects, and covariate imbalances are particularly likely in cluster-randomized trials of quality improvement interventions. When such trials are embedded in medical systems with available automated records, use of these data can enhance the design of the trial.
引用
收藏
页码:S38 / S43
页数:6
相关论文
共 30 条
[1]   Patterns of intra-cluster correlation from primary care research to inform study design and analysis [J].
Adams, G ;
Gulliford, MC ;
Ukoumunne, OC ;
Eldridge, S ;
Chinn, S ;
Campbell, MJ .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2004, 57 (08) :785-794
[2]   IMPROVING DRUG-THERAPY DECISIONS THROUGH EDUCATIONAL OUTREACH - A RANDOMIZED CONTROLLED TRIAL OF ACADEMICALLY BASED DETAILING [J].
AVORN, J ;
SOUMERAI, SB .
NEW ENGLAND JOURNAL OF MEDICINE, 1983, 308 (24) :1457-1463
[3]   Explained variation in a model of therapeutic decision making is partitioned across patient, physician, and clinic factors [J].
Brookhart, MA ;
Solomon, DH ;
Wang, P ;
Glynn, RJ ;
Avorn, J ;
Schneeweiss, S .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2006, 59 (01) :18-25
[4]   CONSORT statement: extension to cluster randomised trials [J].
Campbell, MK ;
Elbourne, DR ;
Altman, DG .
BMJ-BRITISH MEDICAL JOURNAL, 2004, 328 (7441) :702-708
[5]  
Donner A., 2010, Design and analysis of cluster randomization trials in health research
[6]  
Fleiss J., 1986, Reliability of measurement: the design and analysis of clinical experiments
[7]  
Friedman L.M., 1996, FUNDAMENTALS CLIN TR, V3rd
[8]   ADHERENCE TO ASPIRIN IN THE PREVENTION OF MYOCARDIAL-INFARCTION - THE PHYSICIANS HEALTH STUDY [J].
GLYNN, RJ ;
BURING, JE ;
MANSON, JE ;
LAMOTTE, F ;
HENNEKENS, CH .
ARCHIVES OF INTERNAL MEDICINE, 1994, 154 (23) :2649-2657
[9]   Indications for propensity scores and review of their use in pharmacoepidemiology [J].
Glynn, RJ ;
Schneeweiss, S ;
Stürmer, T .
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2006, 98 (03) :253-259
[10]   Concerns about run-in periods in randomized trials [J].
Glynn, RJ ;
Buring, JE ;
Hennekens, CH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (19) :1526-1526